付坤,柳景华

• 1:首都医科大学附属北京安贞医院
• 2:北京市心肺血管疾病研究所心内科

摘要(Abstract)：

<正>维生素K拮抗剂(vitamin K antagonist,VKA)是一种抗凝剂。通过影响维生素K循环使肝细胞中凝血因子的合成受到抑制、内源性抗钙化蛋白的功能受到干扰,进而产生抗凝和促进血管钙化的作用,而血管钙化可引起类似收缩期高血压的病理改变。基质γ-羧基谷氨酸(gamma carboxy glutamic acid,Gla)蛋白(matrix gla protein,MGP)是一种分泌性抗钙化蛋白,具有维生素K依赖性,其功能发挥与Gla基团有关。

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81070227);; 北京市教育委员会科技计划面上项目(350011120118)

作者(Author): 付坤,柳景华

参考文献(References)：

• [1]Cai Y,Xu MJ,Teng X,et al.Intermedin inhibits vascularcalcification by increasing the level of matrix gamma-carboxyglutamic acid protein.Cardiovasc Res,2010,85:864-873.
• [2]O'Donnell CJ,Shea MK,Price PA,et al.Matrix Gla protein isassociated with risk factors for atherosclerosis but not withcoronary artery calcification.Arterioscler Thromb Vasc Biol,2006,26:2769-2774.
• [3]Mousa SA.Oral direct factor Xa inhibitors,with special emphasison rivaroxaban.Methods Mol Biol,2010,663:181-201.
• [4]Ansell J,Hirsh J,Hylek E,et al.Pharmacology andmanagement of the vitamin K antagonists:American College ofChest Physicians Evidence-Based Clinical Practice Guidelines(8th Edition).Chest,2008,133:160S-198S.
• [5]Proudfoot D,Shanahan CM.Molecular mechanisms mediatingvascular calcification:role of matrix Gla protein.Nephrology(Carlton),2006,11:455-461.
• [6]Beazley KE,Eghtesad S,Nurminskaya MV.Quercetin attenuateswarfarin-induced vascular calcification in vitro independently fromMatrix Gla protein.J Biol Chem,2013,288:2632-2640.
• [7]郭晓强.骨钙素:一种重要的能量代谢调节激素.生命科学,2011,23:102-105.
• [8]Parker BD,Bauer DC,Ensrud KE,et al.Association ofosteocalcin and abdominal aortic calcification in older women:thestudy of osteoporotic fractures.Calcif Tissue Int,2010,86:185-191.
• [9]齐永芬,唐朝枢.血管钙化-血管损伤性疾病的共同病理生理基础.中南医学科学杂志,2011,39:241-245.
• [10]Neve A,Corrado A,Cantatore FP.Osteocalcin:Skeletal andextra-skeletal effects.J Cell Physiol,2013,288:1149-1153.
• [11]Webb JH,Blom AM,Dahlbck B.Vitamin K-dependent proteinS localizing complement regulator C4b-binding protein to thesurface of apoptotic cells.J Immunol,2002,169:2580-2586.
• [12]Anderson HA,Maylock CA,Williams JA,et al.Serum-derivedprotein S binds to phosphatidylserine and stimulates thephagocytosis of apoptotic cells.Nat Immunol,2003,4:87-91.
• [13]Liu D,Guo H,Griffin JH,et al.Protein S confers neuronalprotection during ischemic/hypoxic injury in mice.Circulation,2003,107:1791-1796.
• [14]Collin-Osdoby P.Regulation of vascular calcification by osteoclastregulatory factors RANKL and osteoprotegerin.Circ Res,2004,95:1046-1057.
• [15]Vengrenyuk Y,Kaplan TJ,Cardoso L,et al.Computationalstress analysis of atherosclerotic plaques in ApoE knockout mice.Ann Biomed Eng,2010,38:738-747.
• [16]Golub EE.Biomineralization and matrix vesicles in biology andpathology.Semin Immunopathol,2011,33:409-417.
• [17]Zhu D,Mackenzie NC,Farquharson C,et al.Mechanisms andclinical consequences of vascular calcification.Front Endocrinol(Lausanne),2012,3:95.
• [18]Howe AM,Webster WS.Warfarin exposure and calcification ofthe arterial system in the rat.Int J Exp Pathol,2000,81:51-56.
• [19]Essalihi R,Dao HH,Yamaguchi N,et al.A new model ofisolated systolic hypertension induced by chronic warfarin andvitamin K1 treatment.Am J Hypertens,2003,16:103-110.
• [20]Krueger T,Westenfeld R,Ketteler M,et al.Vitamin Kdeficiency in CKD patients:a modifiable risk factor for vascularcalcification.Kidney Int,2009,76:18-22.
• [21]Westenfeld R,Krueger T,Schlieper G,et al.Effect of vitaminK2 supplementation on functional vitamin K deficiency inhemodialysis patients:a randomized trial.Am J Kidney Dis,2012,59:186-195.
• [22]Schurgers LJ,Aebert H,Vermeer C,et al.Oral anticoagulanttreatment:friend or foe in cardiovascular disease.Blood,2004,104:3231-3232.
• [23]Weijs B,Blaauw Y,Rennenberg RJ,et al.Patients usingvitamin K antagonists show increased levels of coronarycalcification:an observational study in low-risk atrial fibrillationpatients.Eur Heart J,2011,32:2555-2562.
• [24]Brodsky SV,Nadasdy T,Rovin BH,et al.Warfarin-relatednephropathy occurs in patients with and without chronic kidneydisease and is associated with an increased mortality rate.KidneyInt,2011,80:181-189.
• [25]Pazár B,Ea HK,Narayan S,et al.Basic calcium phosphatecrystals induce monocyte/macrophage IL-1beta secretion throughthe NLRP3 inflammasome in vitro.J Immunol,2011,186:2495-2502.
• [26]Ewence AE,Bootman M,Roderick HL,et al.Calciumphosphate crystals induce cell death in human vascular smoothmuscle cells:a potential mechanism in atherosclerotic plaquedestabilization.Circ Res,2008,103:e28-e34.
• [27]Ozer N,Cam N,Tangurek B,et al.The impact of CYP2C9 andVKORC1 genetic polymorphism and patient characteristics uponwarfarin dose requirements in an adult Turkish population.HeartVessels,2010,25:155-162.
• [28]Wadelius M,Chen LY,Lindh JD,et al.The largest prospectivewarfarin-treated cohort supports genetic forecasting.Blood,2009,113:784-792.
• [29]Kimura R,Miyashita K,Kokubo Y,et al.Genotypes of vitaminK epoxide reductase,gamma-glutamyl carboxylase,andcytochrome P450 2C9 as determinants of daily warfarin dose inJapanese patients.Thromb Res,2007,120:181-186.
• [30]Chen LY,Eriksson N,Gwilliam R,et al.Gamma-glutamylcarboxylase(GGCX)microsatellite and warfarin dosing.Blood,2005,106:3673-3674.
• [31]Shuen AY,Wong BY,Fu L,et al.Evaluation of the warfarin-resistance polymorphism,VKORC1 Asp36Tyr,and its effect ondosage algorithms in a genetically heterogeneous anticoagulantclinic.Clin Biochem,2012,45:397-401.